China NMPA Establishes Patent Linkage Registration Platform

On May 18, 2021, China’s Center for Drug Evaluation of National Medical Products Administration (NMPA) issued the “Notice on the public testing of the patent information registration platform related to the early settlement mechanism of drug patent disputes and other related matters”.  

The patent information registration platform is established for listed drugs in China, to implement a mechanism for the early resolution of drug patent disputes.  

The new platform is available for public testing purposes until 31 May 2021, at 

Marketing Authorization Holders with drugs marketed in China are encouraged to participate for the filing of relevant drug patent information and provide opinions to improve the platform. 

The drug patent information submitted during testing will be disclosed after confirmation by the drug marketing license holder upon implementation.  

The platform will include chemical generic drugs, traditional Chinese medicines and biosimilars with the same name. 

Link: 关于药品专利纠纷早期解决机制相关专利信息登记平台公开测试等有关事宜的通知 

Share on Linkedin Send to Email

Questions? Request more information from our specialists!

Contact Us

More News